



Rec'd PGT/PTO 25 NOV 2005

ATTORNEY DOCKET NO. 21101.0021U2
APPLICATION NO. 10/516,662
SHEET 1 OF 4

| | | |
|---|----------------------|--------------------|
| INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary) | Complete If Known | |
| | Application Number | 10/516,662 |
| | Filing Date | June 2, 2003 |
| | First Named Inventor | Bock et al. |
| | Group Art Unit | Unassigned 1656 |
| | Examiner Name | Unassigned CARLSON |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----------|--------------|----------|---------------------|-------|------------|------------------------------|
| Examiner's Initials | Cite No. | Document No. | Date | Name | Class | Subclasses | Filing Date (if appropriate) |
| rep | A1 | 6,878,813 | 04/12/05 | Bock et al. | 530 | 393 | 12/11/01 |
| | A2 | 5,204,253 | 04/20/93 | Sanford et al. | 435 | 459 | |
| | A3 | 5,420,252 | 05/30/95 | Kato et al. | 530 | 393 | |
| | A4 | 5,618,713 | 04/08/97 | Zettlemeissl et al. | 435 | 226 | |
| | A5 | 5,700,663 | 12/23/97 | Zettlemeissl et al. | 435 | 69.6 | |
| rep | A6 | 5,843,705 | 12/01/98 | DiTullio et al. | 800 | 7 | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|----------|--|----------|-----------------------|-----------------------|
| Examiner's Initials | Cite No. | Foreign Patent Document Country Code-Number-Kind Code | Date | Name | Translation Yes/No |
| rep | A7 | EP 0 568 833 A1 | 08/04/93 | Kato et al. | |
| | A8 | WO 90/09737 | 07/09/90 | Blood Research Center | |
| | A9 | WO 91/00291 | 01/10/91 | Akzo | |
| | A10 | WO 95/05853 | 03/02/95 | Carson et al. | |

| NON-PATENT DOCUMENTS | | |
|----------------------|----------|---|
| Examiner's Initials | Cite No. | Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication) |
| KCC | A11 | Backovic and Gettins, "Insight into residues critical for antithrombin function from an expanded database of sequences that includes frog, turtle and ostrich antithrombins." J. Proteome Res. 2002 1:367-373. |
| | A12 | Bayston et al. "Familial overexpression of beta antithrombin caused by an Asn135Thr substitution." Blood 1999 93:4242-7. |
| | A13 | Bick et al. "Antithrombin III patterns in disseminated intravascular coagulation." Am. J. Clin. Pathol. 1980 73(4):577-83. |
| | A14 | Blauhut et al. "Substitution of antithrombin III in shock and DIC: a randomized study." Thromb. Res. 1985 39(1):81-9. |
| | A15 | Bock et al., "Cleaved and inactivated antithrombin III in bronchoalveolar lavage (BAL) samples from acute respiratory distress (ARDS) and at-risk for ARDS patents," Proteases/Antiproteases, seminar, Amer. J. Respir. Crit. Care Med., 2001, A63. (Poster Abstract) |
| | A16 | Bock et al. "Cloning and expression of the cDNA for human antithrombin III." Nucleic Acids Res. 1982 10(24):8113-25. |
| | A17 | Brennan et al. "Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135." FEBS Lett. 1987 219(2):431-6. |
| | A18 | Buller and Cate, "Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate." Am. J. Med. 1989 87(3B):44S-48S. |
| | A19 | Carlson et al. "Comparison of the behavior in vivo of two molecular forms of antithrombin III." Biochem. J. 1985 225:557-64. |
| | A20 | Carrell and Owen, "Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis." Nature. 1985 317(6039):730-2. |
| | A21 | Cohen et al. "In vivo inactivation of antithrombin III is promoted by heparin during cardiopulmonary bypass." J. Invest. Surg. 1992 5:45-9. |
| KCC | A22 | Cunningham et al. "Development of an elastase-resistant antithrombin through mutagenesis at P4." Blood. 1995 86(10 Supp.):375A. (Abstract) |

| | |
|--|------------------------------------|
| Examiner Signature: <i>K Carlson</i> | Date Considered: <i>11-7-07</i> |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

Rec'd PCT/PTO 25 NOV 2005

ATTORNEY DOCKET NO. 21101.0021U2

APPLICATION NO. 10/516,662

SHEET 2 OF 4

| INFORMATION DISCLOSURE STATEMENT LIST | | Complete if Known | |
|--|---|--|--------------------|
| | | Application Number | 10/516,662 |
| | | Filing Date | June 2, 2003 |
| | | First Named Inventor | Bock <i>et al.</i> |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| (Use as many sheets as necessary) | | | |
| KCC | A23 | Cunningham et al. "Impact of mutations at the P4 and P5 position on the reation of antithrombin with thrombin and elastase." Thromb. Res. 1997 88(2):171-81. | |
| | A24 | Damus and Wallace, "Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy." Thromb Res. 1975 6(1):27-38. | |
| | A25 | deAgostini et al. "Localization of anticoagulant active heparan sulfate proteoglycans in vascular endothelium: Antithrombin binding on cultured endothelial cells and perfused rat aorta." J. Cell Biol. 1990 111:1293-1304. | |
| | A26 | Delshammar et al. "Abnormal proteolysis (DIC)--successful treatment with antithrombin III concentrate and a concentrate containing F XIII and native von Willebrand factor." J. Intern. Med. 1989 225(1):21-7. | |
| | A27 | Dickneite and Paques, "Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis." Thromb Haemost. 1993 69(2):98-102. | |
| | A28 | Dunzendorfer et al. "Cell-surface heparan sulfate proteoglycanmediatedregulation of human neutrophil migration by the serpin antithrombin III." Blood 2001 97:1079-85. | |
| | A29 | Emerson et al. "Efficacy of antithrombin III supplementation in animal models of fulminant Eschericia coli endotoxemia or bacteremia." Am. J. Med. 1989 87:27S-33S. | |
| | A30 | Emerson et al. "Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat." Circ Shock. 1987 21(1):1-13. | |
| | A31 | Ersdal-Badju et al. "Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirusinfected insect cells." Biochem. J. 1995 310:323-30. | |
| | A32 | Fourrier et al. "Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation." Chest. 1993 104(3):882-8. | |
| | A33 | Franzen et al. "Structural studies on the carbohydrate portion of human antithrombin III." J. Biol. Chem. 1980 255(11):5090-3. | |
| | A34 | Frebelius et al. "Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT-beta." Thromb. Vasc. Biol. 1996 16:1292-7. | |
| | A35 | Hedin et al. "Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells." Arterioscler Thromb. 1994 14(2):254-60. | |
| | A36 | Hellgren et al. "Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients." Thromb Res. 1984 35(4):459-66. | |
| | A37 | Hellgren et al. "Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients." Intensive Care Med. 1984 10(1):23-8. | |
| | A38 | Hoffmann et al. "Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium." Crit. Care Med. 2002 30:218-25. | |
| | A39 | Ishiguro, K. et al. "Complete antithrombin deficiency in mice results in embryonic lethality." J. Clin. Invest. 2000 106(7):873-878. | |
| | A40 | Jairajpuri et al. "Elimination of P1 arginine-393 interaction with underlying glutamic acid-255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition." J. Biol. Chem. 2002 277:24460-5. | |
| | A41 | Jochum et al. "Effect of human granulocytic elastase on isolated human antithrombin III." Hoppe Seylers Z Physiol Chem. 1981 362(2):103-12. | |
| A42 | Jochum, "Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation." Semin Hematol. 1995 32(4 Suppl 2):19-32. | | |
| KCC | A43 | Jordan et al. "Heparin promotes the inactivation of antithrombin by neutrophil elastase." Science. 1987 237(4816):777-9. | |

| | |
|---------------------------------|-----------------------------|
| Examiner Signature: KCCarson | Date Considered: 11-7-07 |
|---------------------------------|-----------------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

25 NOV 2005

ATTORNEY DOCKET NO. 21101.0021U2
APPLICATION NO. 10/516,662
SHEET 3 OF 4

| INFORMATION DISCLOSURE STATEMENT LIST (Use as many sheets as necessary) | | Complete if Known | |
|---|-----|--|--------------------|
| | | Application Number | 10/516,662 |
| | | Filing Date | June 2, 2003 |
| | | First Named Inventor | Bock <i>et al.</i> |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| rec | A44 | Jordan, "Antithrombin in vertebrate species: conservation of the heparin-dependent anticoagulant mechanism." Arch. Biochem. Biophys. 1983 227(2):587-95. | |
| | A45 | Kato et al. "Recombinant antithrombin III mutations with enhanced antithrombin activity without heparin." 69 th Scientific Sessions, Abstract 4336, 1996 94:8 Supp., p. I-741. (Abstract) | |
| | A46 | Kocsis et al. "Heparin-coated stents." J. Long-Term Effects of Medical Implants. 2000 10:19-45. | |
| | A47 | Kurachi et al. "Inhibition of bovine factor IXa and factor Xbeta by antithrombin III." Biochemistry. 1976 15(2):373-7. | |
| | A48 | Lammle et al. "Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC)." Am. J. Clin. Pathol. 1984 82(4):396-404. | |
| | A49 | Lawson et al. "Complex-dependent inhibition of factor VIIa by antithrombin III and heparin." J. Biol. Chem. 1993 268(2):767-70. | |
| | A50 | Mammen et al. "Human antithrombin concentrates and experimental disseminated intravascular coagulation." Semin. Thromb. Hemost. 1985 11(4):373-83. | |
| | A51 | Mant et al. "Haemorrhagic complications of heparin therapy." Lancet. 1977 1(8022):1133-5. | |
| | A52 | Marcum et al. "Microvascular heparin-like species with anticoagulant activity." Am. J. Physiol. 1983 245(5 Pt 1):H725-33. | |
| | A53 | Minnema et al. "Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli." Blood. 2000 95(4):1117-23. | |
| | A54 | Mizuochi et al. "Structural studies of the carbohydrate moiety of human antithrombin III." Arch. Biochem. Biophys. 1980 203(1):458-65. | |
| | A55 | Nakajima et al., "Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase," J. Biol. Chem. 1979 254:4027. | |
| | A56 | Nuijens et al. "Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis." J. Lab. Clin. Med. 1992 119(2):159-68. | |
| | A57 | O'Reilly et al. "Antiangiogenic activity of the cleaved conformation of the serpin antithrombin." Science. 1999 285(5435):1926-8. | |
| | A58 | Oelschläger et al. "Antithrombin III inhibits nuclear factor kappa B activation in human monocytes and vascular endothelial cells." Blood 2002 99:4015-20. | |
| | A59 | Olson et al. "Identification of critical molecular interactions mediating heparin activation of antithrombin. Implications for the design of improved heparin anticoagulants." Trends Cardiovasc. Med. 2002 12:198-205. | |
| | A60 | Olson et al. "Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement." J. Biol. Chem. 1992 267(18):12528-38. | |
| | A61 | Ostrovsky et al. "Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion." Circulation. 1997 96(7):2302-10. | |
| | A62 | Owen et al. "P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase. Implications for the heparin activation mechanism." FEBS Lett. 1991 280(2):216-20. | |
| | A63 | Petersen et al., Primary structure of antithrombin III (heparin cofactor) - partial homology between alpha 1-antitrypsin and antithrombin-III." The Physiological Inhibitors of Coagulation and Fibrinolysis, Elsevier/North Holland Biomedical Press. 1979 pp. 43-54. | |
| rec | A64 | Peterson and Blackburn, "Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding." J. Biol. Chem. 1985 260(1):610-5. | |

| | |
|--|------------------------------------|
| Examiner Signature: <i>K C Carlson</i> | Date Considered: <i>11-7-07</i> |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| INFORMATION DISCLOSURE STATEMENT LIST | | Complete if Known | |
|---------------------------------------|---|--|--------------------|
| | | Application Number | 10/516,662 |
| (Use as many sheets as necessary) | | Filing Date | June 2, 2003 |
| | | First Named Inventor | Bock <i>et al.</i> |
| | | Group Art Unit | Unassigned |
| | | Examiner Name | Unassigned |
| rcc | A65 | Picard and Bock, "Rapid and efficient one-tube PCR-based mutagenesis method." <i>Methods in Mol. Biol.</i> Vol. 67, PCR Cloning Protocols. From molecular cloning to genetic engineering. B.A. White Humana Press, Totowa, NJ, 1996, 183-8. | |
| | A66 | Picard <i>et al.</i> "A rapid and efficient one-tube PCR-based mutagenesis technique using Pfu DNA polymerase." <i>Nucleic Acid Res.</i> 1994 22(13):2587-91. | |
| | A67 | Picard <i>et al.</i> "Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity." <i>Biochemistry.</i> 1995 34(26):8433-40. | |
| | A68 | Rao <i>et al.</i> "Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa." <i>Blood.</i> 1993 81(10):2600-7. | |
| | A69 | Rosenberg and Damus, "The purification and mechanism of action of human antithrombin-heparin cofactor." <i>J. Biol. Chem.</i> 1973 248(18):6490-505. | |
| | A70 | Rosenberg, "Chemistry of the hemostatic mechanism and its relationship to the action of heparin." <i>Fed. Proc.</i> 1977 36(1):10-8. | |
| | A71 | Rothenburger <i>et al.</i> "Treatment of thrombus formation associated with the MicroMed DeBakey VAD using recombinant tissue plasminogen activator." <i>Circulation</i> 2002 106(suppl 1): I-189-92. | |
| | A72 | Ruf and Mueller, "Tissue factor in cancer angiogenesis and metastasis." <i>Curr. Opin. Hematol.</i> 1996 3(5):379-84. | |
| | A73 | Seitz <i>et al.</i> "Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections." <i>Eur. J. Haematol.</i> 1987 38(3):231-40. | |
| | A74 | Stephens <i>et al.</i> "Site directed mutagenesis of the reactive center (serine 394) of antithrombin III." <i>J. Biol. Chem.</i> 1988 263(31):15849-52. | |
| | A75 | Tani <i>et al.</i> "Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis." <i>Am. J. Respir. Cell Mol. Biol.</i> 1991 5(1):34-40. | |
| | A76 | Tejada, M.L. and Deeley, R.G. "Cloning of an avian antithrombin: developmental and hormonal regulation of expression." <i>Thromb. Haemost.</i> 1995 73(4):654-661. | |
| | A77 | Turk <i>et al.</i> "The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change." <i>Biochemistry.</i> 1997 36(22):6682-91. | |
| | A78 | Uchiba <i>et al.</i> "Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III." <i>Semin. Thromb. Hemost.</i> 1997 23(6):583-90. | |
| | A79 | van Boven and Lane, "Antithrombin and its inherited deficiency states." <i>Semin. Hematol.</i> 1997 34(3):188-204. | |
| | A80 | Varga <i>et al.</i> "Infectious entry pathway of adenovirus type 2." <i>J. Virol.</i> 1991 65(11):6061-70. | |
| | A81 | Vinazzer, "Antithrombin III in shock and disseminated intravascular coagulation." <i>Clin. Appl. Thrombosis/Hemostasis.</i> 1995 1:62-5. | |
| | A82 | Warren <i>et al.</i> "High-dose antithrombin III in severe sepsis: a randomized controlled trial." <i>JAMA.</i> 2001 286(15):1869-78. | |
| | A83 | Witmer and Hatton, "Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelialized aortic wall in vitro and in vivo." <i>Arteriosclerosis and Thrombosis.</i> 1991 11:530-9. | |
| A84 | Wolff <i>et al.</i> "Direct gene transfer into mouse muscle in vivo." <i>Science.</i> 1990 247(4949 Pt 1):1465-8. | | |
| rcc | A85 | Zendeherouh, Ph.D. Dissertation, "Novel proteinase inhibitors for use in treatment of sepsis." Temple Univ. School of Medicine, publically available at the Univeristy of Michigan dissertation archive in 1999. | |

| | |
|--|------------------------------------|
| Examiner Signature: <i>MCCarson</i> | Date Considered: <i>11-7-07</i> |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

#2

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|----------------------|-------------------|
| Application Number | 10/516,662 |
| Filing Date | 3/13/2006 |
| First Named Inventor | Bock et al. |
| Group Art Unit | 1656 |
| Examiner Name | Carlson, Karen C. |

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON-PATENT DOCUMENTS

Examiner Signature:

Signature: B. C. Carlsen

Date Considered:

11-7-07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.